A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma

Key Inclusion Criteria

• Men and women between the age of 18-75 years.
• Participants with B-cell lymphoma (defined by World Health Organization classification) refractory or relapsed following at least one line of therapy.
• Judged by the investigator as requiring treatment.
• Eastern Cooperative Oncology Group performance status of 0-1.
• Life expectancy of at least 4 months.
• Adequate hematological function.
• Adequate renal function.
• Adequate liver function.
• Adequate coagulation function.
• Female participants of childbearing potential and non-sterile males must have practiced at least one of the following methods of birth control with partner(s) throughout the study and for 90 days after discontinuing study drug: total abstinence from sexual intercourse, double-barrier contraception, intrauterine device or hormonal contraceptive initiated at least 3 months prior to first dose of study drug.
• Male participants must not have donated sperm from start of study drug administration, until 90 days after discontinuation of treatment.

Key Exclusion Criteria

• With central nervous system involvement of the disease.
• The pathological type of the disease had disease transformation.
• Had underdone allogeneic hematopoietic stem cell transplantation.
• Had received corticosteroid anti-neoplastic treatment within 7 days before the first dose, has received radiotherapy and chemotherapy within 4 weeks before the first dose or has received treatment with monoclonal antibody within 4 weeks before the first dose.
• Had received BTK inhibitor treatment prior to enrollment.
• Had received chemotherapy and has not yet recovered from toxicity
• Had received Chinese herbal medicine as anti-neoplastic therapy within 4 weeks before starting study treatment.
• History of other malignancies within 2 years before study.
• With uncontrolled systemic infection.
• Major surgery in the past 4 weeks.
• With known HIV, or active hepatitis B or hepatitis C virus infection.
• With cardiovascular disease of New York Heart Association Classification ≥ 3.
• Significant electrocardiogram abnormalities.
• Significant active renal, neurologic, psychiatric, hepatic or endocrinologic disease that in the investigator's opinion would adversely impact on his/her participation in the study.
• Inability to comply with study procedures.
• Was currently taking anticoagulant drugs.
• Was currently taking potent cytochrome P450 3A inhibitor or inducer.
• Had stroke or cerebral hemorrhage within 6 months before enrollment.

Note: Other protocol defined Inclusion/Exclusion criteria may have applied.